Both in Biotechnology
Prime Medicine vs Cullinan Therapeutics
Over the past year PRME returned +15.6% and CGEM returned +68.8%; their daily moves had a correlation of 0.38.
PRME +15.6% CGEM +68.8%Growth of $1, one year, split-adjusted
| Metric | PRME | CGEM |
|---|---|---|
| Price | $4.97 | $12.49 |
| Market cap | $901.4M | $803.8M |
| Today | +9.23% | −20.70% |
| 1 month | +42.0% | −23.1% |
| 6 months | +45.7% | −16.7% |
| Year to date | +43.2% | +20.7% |
| 1 year | +9.0% | +59.9% |
| Revenue growth (YoY) | +3.5% | — |
| Gross margin | 100.0% | — |
| Net margin | −3649.0% | — |
| P/E (TTM) | — | — |
| Price / sales | 221.3× | — |
| Net cash | $95.1M | $334.5M |
| Dividend yield | — | — |
| Volatility (60d) | 112.8% | 87.7% |
| Short % of float | 34.4% | 14.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).